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Abstract
The opportunistic fungal pathogen Candida glabrata is a frequent cause of candidiasis, causing infections ranging from
superficial to life-threatening disseminated disease. The inherent tolerance of C. glabrata to azole drugs makes this
pathogen a serious clinical threat. To identify novel genes implicated in antifungal drug tolerance, we have constructed a
large-scale C. glabrata deletion library consisting of 619 unique, individually bar-coded mutant strains, each lacking one
specific gene, all together representing almost 12% of the genome. Functional analysis of this library in a series of
phenotypic and fitness assays identified numerous genes required for growth of C. glabrata under normal or specific stress
conditions, as well as a number of novel genes involved in tolerance to clinically important antifungal drugs such as azoles
and echinocandins. We identified 38 deletion strains displaying strongly increased susceptibility to caspofungin, 28 of which
encoding proteins that have not previously been linked to echinocandin tolerance. Our results demonstrate the potential of
the C. glabrata mutant collection as a valuable resource in functional genomics studies of this important fungal pathogen of
humans, and to facilitate the identification of putative novel antifungal drug target and virulence genes.
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Introduction
Candida glabrata, a small, asexual, haploid yeast, is the second
most frequent cause of candidiasis after Candida albicans, account-
ing for approximately 15%–25% of clinical cases [1–4]. C. glabrata
forms part of the normal microbial flora in humans, but can cause
serious infections in immunocompromised and hospitalized
patients; antibiotic exposure and presence of central venous
catheter devices, being additional important risk factors for disease
development [2]. In contrast to the pleomorphic diploid C. albicans
[5], C. glabrata is found clinically, exclusively as monomorphic
yeast cells. It also lacks several attributes considered key mediators
of fungal pathogenicity in other Candida spp, such as secretion of
proteases and lipases [6,7]. Despite the apparent absence of these
well-known fungal virulence traits, C. glabrata remains highly
pathogenic to humans. Hence, C. glabrata may rely upon distinct
strategies and other virulence attributes to initiate infection, as well
as to persist in infected patients.
Some traits that have been linked to the clinical importance and
virulence of C. glabrata include an inherently elevated tolerance to
azole antifungals [8–11]; the presence of a large repertoire of
telomere-associated adhesins [12–18]; melanin-like pigment pro-
duction [19]; adaptation to the acidic phagosomal environment
and intra-phagosomal survival [20–22]; and Ace2-dependent
components of the cell wall [23]. However, it is clear that the
molecular basis of C. glabrata virulence is far from being completely
understood.
C. glabrata clinical isolates generally exhibit a high inherent
tolerance level to azole drugs [9]. While this trait has been
extensively studied, the underlying mechanisms remain incom-
pletely explained. Azole resistance can be acquired through
increased expression of genes encoding ABC transporters (Cdr1,
Pdh1, Snq2) or changes in their transcriptional regulatory system
(Pdr1, Gal11) [24–28]. Mitochondrial dysfunction [29] and serum
utilization via the putative sterol transporter Aus1 [30,31] also
impact the ability of C. glabrata to tolerate high azole levels.
Notably, calcineurin signaling has been implicated in azole
tolerance in C. glabrata [32]. It remains unclear if these are the
only mechanisms driving azole resistance in C. glabrata. However,
the clinical implications of this resistance demand alternative
antifungals for effective treatment of C. glabrata infections in
patients, especially since C. glabrata infections are globally rising,
sometimes accounting for more than 30% of clinical cases [33].
Echinocandins such as caspofungin (CF), anidulafungin and
micafungin are a relatively new class of effective yet high-cost
antifungal drugs targeting fungal 1,3-b-D-glucan synthases and
thereby impairing cell wall integrity [34]. Mutations in subunits of
glucan synthases can render fungi resistant to echinocandin [34–
37]. Surprisingly, even ectopic overexpression of the C. albicans
Cdr2 efflux ABC transporter gene in both laboratory strains and
clinical isolates markedly increases CF tolerance [38]. Further-
more, the Hsp90 heat shock protein has also been identified as a
regulator of echinocandin tolerance acting through calcineurin
signaling [36,39]. However, a better understanding of molecular
mechanisms modulating echinocandin susceptibility is necessary,
since it may facilitate targeted drug discovery, especially in the case
of emerging resistant strains [40]. Importantly, an increase in the
number of echinocandin resistant C. glabrata clinical isolates has
been reported recently, implying that many genes can contribute
to echinocandin tolerance [41].
Reverse genetics coupled with global functional profiling has
proven a powerful approach to identify genes required for specific
phenotypes. Functional genomics studies in the non-pathogenic
yeast S. cerevisiae have provided the starting point to decipher
genotype-phenotype relations as they enabled answers about
fundamentally important questions concerning complex genetic
interactions and the genetic landscape of yeast. These approaches
also unraveled stress response mechanisms and provided new
insights into drug susceptibility and morphogenesis [42–49].
Heroic efforts by a few groups have recently resulted in highly
useful genome-scale deletion collections of the major pathogen C.
albicans [50–52] and Cryptococcus neoformans [53], enabling the
identification of novel virulence genes and further demonstrating
the power of a functional genomics approach.
Here, we have adapted a semi-automated approach [51] for
constructing gene deletions to generate a collection of individually
bar-coded strains in the sequenced C. glabrata strain ATCC2001
[54], each lacking one defined open reading frame. We took
advantage of this library to undertake the first systematic
functional-genomic and phenotypic analysis of C. glabrata, in
particular examining the response to traits putatively implicated in
virulence and antifungal tolerance of this human pathogen of
increasing importance and prevalence. We performed a series of
growth assays in distinct media to determine the impact of gene
deletion on fitness. We then determined the susceptibility of the
collection to major antifungal compounds (including azoles and
caspofungin) and various other cell wall-damaging compounds.
Finally, we investigated the effect on cellular morphology on
fitness in vitro, and the ability to form biofilms. This enabled us to
generate the first large-scale chemogenetic and phenotypic profile
of C. glabrata. Our analysis revealed numerous novel genes
implicated in stress response, cell wall homeostasis, growth
morphology and fitness. Most importantly, we discovered numer-
ous novel genes implicated in susceptibility to echinocandins,
demonstrating the usefulness of this deletion collection for the
functional analysis of virulence-related, as well as clinically




Using a large-scale phylogenetic approach across many fungal
species [55], we identified 1047 putatively non-essential candidate
genes in C. glabrata representing functional GO categories such as
environmental stress sensing and signaling (MAPK pathways,
TOR, RIM, PKA), transcriptional regulation, antifungal drug
resistance (PDR network, membrane permeases), cell wall
structure and homeostasis (glucan, mannan, chitin synthesis,
Author Summary
Clinical infections by the yeast-like pathogen Candida
glabrata have been ever-increasing over the past years.
Importantly, C. glabrata is one of the most prevalent
causes of drug-refractory fungal infections in humans. We
have generated a novel large-scale collection encompass-
ing 619 bar-coded C. glabrata mutants, each lacking a
single gene. Extensive profiling of phenotypes reveals a
number of novel genes implicated in tolerance to
antifungal drugs that interfere with proper cell wall
function, as well as genes affecting fitness of C. glabrata
both during normal growth and under environmental
stress. This fungal deletion collection will be a valuable
resource for the community to study mechanisms of
virulence and antifungal drug tolerance in C. glabrata,
which is particularly relevant in view of the increasing
prevalence of infections caused by this important human
fungal pathogen.
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glycosylation, adhesins, glycosylphosphatidylinositol (GPI)-an-
chor), chromatin and histone modification, iron metabolism and
metal sensitivity, as well as peroxisome biogenesis. We also selected
genes lacking obvious orthologues in S. cerevisiae (Table S1).
Parental recipient strains
To enable the rescue of deletion phenotypes, and to facilitate
double- or triple mutant construction, we engineered a triple-
auxotrophic recipient strain in the sequenced strain C. glabrata
ATCC 2001 [54]. We used the dominant recyclable nourseo-
thricin resistance marker SAT1 [56] to replace the coding
sequences of HIS3, LEU2 and TRP1 (Figure S1A). The repeated
use of this marker cassette resulted in the new C. glabrata
background recipient strain for deletions referred to as HTL
(his3D::FRT leu2D::FRT trp1D::FRT), as well as all possible
isogenic single deletions and all combinations of double deletion
strains (Table S2). We also constructed a bar-coded version of the
HTL strain, C. glabrata HTL reference, by inserting 20 bp
barcodes flanking the trp1 locus (Table S2).The transcription
factor (TF) mutants were made in a his3 derivative of ATCC2001,
the majority using a codon-optimized version of the NAT1 marker
[57]. We avoided the use of the URA3 marker in C. glabrata, since it
is known to alter virulence properties of C. albicans [58,59]. The
HTL strain displayed similar growth properties and rates as the
parental strain, on both minimal and full media (Figure S1C).
Importantly, the auxotrophic markers did not significantly
influence growth in vitro, or the survival in immunocompetent
mice when compared to the parental wild type strain [60]. While
the growth behavior of C. glabrata HTL was largely unchanged,
these cells reached a slightly lower maximal cell density when
growing in minimal media when compared to wild type cells
(Figure S1C).
Gene deletion strategy
Targeted gene disruption with short-homology flanking regions,
as was done to construct the S. cerevisiae knock-out library, is
inefficient in C. glabrata. Higher targeting efficiency requires the
use of $500 base pair (bp) flanking regions [61]. Therefore, to
maximize efficiency of gene replacement, we adapted and
automated the fusion PCR technique [51] to generate gene
deletion constructs containing ,500 bp homologous flanking
regions for every gene, fused to the dominant marker NAT1 and
flanked by unique barcode identifiers (Figure 1A). We employed a
limited set of barcode sequences selected from those successfully
used in the S. cerevisiae genome deletion project [43,49]. These
barcodes enable quantification and tracking of single mutants in
pool experiments. A complete list of all barcode sequences
corresponding to each deleted ORF in the collection is given in
Table S3.
C. glabrata recipient strains were transformed with these deletion
cassettes using a modified 96-well format electroporation protocol.
All resulting nourseothricin-resistant transformants were tested for
Figure 1. Generation of C. glabrata mutants and systematic phenotypic analysis. (a) Generation of gene deletion constructs by fusion PCR
using the dominant selectable marker NAT1. A set of two times 96 unique barcode sequences was integrated in oligonucleotides to amplify the
marker fragment and to add overlap sequences. (b) Transformants were verified by colony PCR for correct integration on the 59 and 39 junction and
checked for absence of the target ORF. (c) Overview of the construction of the gene deletion strain library.
doi:10.1371/journal.ppat.1004211.g001
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Figure 2. Relative fitness distribution and morphology of C. glabrata gene deletion strains. (a) Wild type and mutant strains were grown in
rich medium at 30uC and doubling times were recorded. The median doubling time of the wild type C. glabrata ATCC2001 strain under these
conditions was 63.9 min while the median for mutant strains was 68.1 min. For each strain, the relative fitness was calculated using doubling times
from at least two independent cultures of 1–6 independent mutants. Strains that showed strong variations in relative fitness between independent
mutants or independent cultures were omitted from further analysis (Table S5). Data were obtained for 503 knock-out mutants (Table S6). (b) Colony
and cell morphologies of C. glabrata deletion strains. Different types of distinct cell and colony morphologies were found. Cell morphology classes:
ellipsoid (a), chains (b, f, g, i, k, l), elongated (c, d), large clumps (d, j, m, n), round (e), large and round (h); colony morphologies: smooth (a, b, c, e, f, g,
i), small (h), slightly wrinkled (k, l), wrinkled (d, j, m, n). WT=HTL background strain; white bars correspond to 10 mm.
doi:10.1371/journal.ppat.1004211.g002
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correct genomic integration by colony PCR to verify both 59 and
39 junctions (Figure 1B). Single colonies of up to six verified
transformants for each gene were isolated; the absence of the
corresponding gene from the genome was confirmed using
another PCR-based step and confirmed gene deletion strains
were cryo-preserved (Figure 1B, C). A total of 24 PCR-verified
gene deletion strains were randomly selected and subjected to
Southern blot analysis to confirm correct genomic replacements
(data not shown).
In all, we successfully deleted 619 of the 1047 genes initially
selected for inactivation, yielding a total of 1601 independent
unique deletion strains (Table S3; http://funpath.cdl.univie.ac.at),
representing 59% of the selected genes and about 12% of the
entire C. glabrata genome. Notably, for 77 genes only one deletion
was obtained, while the majority of deletions result from two (246)
or three (224) independent transformation and thus genomic
removal events (Table S3). We assume that a large fraction of the
genes that we failed to inactivate is a consequence of inefficient
homologous targeting, rather than a true representation of the
frequency of essential genes.
Validation of screening conditions
Fungal pathogens need to adapt to diverse host immune defense
mechanisms and environmental stresses. Relevant stress conditions
employed include perturbations of cell wall integrity, osmostress
during phagolysosome maturation and growth at elevated
temperature as well as often exposure to antifungal drugs. An
efficient adaptation to particular stress conditions may also include
formation of biofilms. We therefore phenotypically profiled the
mutant collection to identify genes implicated in the response to
host-mimicking adverse conditions. First, we carried out a
preliminary pilot screen using a small set of selected deletion
mutants displaying known phenotypes. Mutants lacking genes of
the high osmolarity glycerol (HOG) pathway, the cell integrity
protein kinase C (PKC) pathway and the pleiotropic drug
resistance (PDR) network were tested for growth under conditions
known to affect the corresponding mutants in S. cerevisiae. As
expected, lack of PBS2, encoding the central MAPK (mitogen-
activated protein kinase) of the HOG pathway [62], resulted in
severe osmosensitivity (Figure S2A). Likewise, azole hypersensitiv-
ity was observed in cdr1 and pdr1 strains (Figure S2B) [24–
26,28,63,64]. Finally, as previously shown cells lacking the Slt2
kinase of the PKC pathway [65,66] displayed drastic hypersen-
sitivities to CF (Figure S2C).
Following these initial experiments, which served to establish
and validate screening parameters, the collection of 1601 gene
deletion mutants was subjected to extensive phenotypic profiling in
four independent laboratories using the same conditions. The
deletion library was screened for various phenotypes, including
growth defects in YPD at 30uC, defects in biofilm formation,
sensitivities against antifungal drugs (azoles, amphotericin B
(AmB)) in liquid medium, and cell wall-perturbing agents (Congo
Red (CR), Calcofluor White (CW) and CF), as well as heat stress
(42uC) and osmostress (NaCl) on solid media. Furthermore,
colonies were also inspected for obvious morphology alterations. A
total number of 196 mutants showed phenotypes different from
the wild type control for at least one condition tested. A summary
of all of these mutants with their phenotypes is provided in Table
S4.
Growth and fitness defects
Changes in the pathogenic potential of a fungus may be
associated with a gain or loss of in vitro or in vivo growth, influencing
the ability to efficiently replicate in the host or to withstand
antifungal treatment [67]. Thus, we measured the growth rates of
individual mutants in the deletion collection in YPD at 30uC. For
Figure 3. Relative biofilm fitness distribution. Wild type and mutant strains were induced to form biofilms in 96-well polystyrene plates in
minimal medium at 37uC and the biofilm biomass was quantified using fluorescein diacetate (FDA). For each strain, a relative biofilm fitness was
calculated based on FDA hydrolysis data from at least two independent cultures. Data were obtained for 420 knock-out mutants (Table S9). Strains
that showed strong variations in relative fitness between independent mutants or independent cultures were omitted from further analysis (Table
S8).
doi:10.1371/journal.ppat.1004211.g003
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each deletion strain, a relative fitness index [68] was calculated
using the doubling times from at least two independent cultures of
1–6 independent mutants, and compared to the doubling time of
all other strains. Notably, we identified 57 deletion mutants
showing strong variations in relative fitness between independent
cultures (Table S5), all of which were omitted from further analysis
along with deletions that were present in duplicate. Hence,
reproducible fitness data could be obtained for 503 unique
mutants (representing 1125 deletions). Out of these gene knock-
outs, 402 had a relative fitness index within two standard
deviations (SD) of the average relative fitness (Figure 2A, Table
S6). These data suggested that the corresponding genes are not
necessary for efficient planktonic growth of C. glabrata in YPD at
30uC. However, 70 strains showed a significant fitness defect
(doubling time of $2 SD below the average fitness). Interestingly,
another 34 deletions showed a gain in fitness (doubling time of $2
SD above the average fitness) under these growth conditions
(Figure 2A, Table S7).
A total of 13 deletion strains showed obvious alterations of both
colony and cellular morphology (Figure 2B). Five of these mutants
were also shown to exhibit fitness defects in vitro (Table S6). Most
morphology mutants grew as small or large wrinkled or smooth
colonies. Microscopic inspection of deletion mutant phenotypes
allowed for further classification into different cell morphology
classes, including round cells (dse2, tos6, ace2, chs3, bni4, cwh41),
giant cells with obvious structural defects (cdc21, cbk1, kre6), cells
with pseudohyphal-like elongated morphologies (gin4), and as
pearl-string-like cells connected to each other as for dse2 mutants
(Figure 2B). Notably, except for pseudohyphal morphologies
[69,70] or small round cells as for ace2 [23], many of these
morphological alterations have not been described in C. glabrata to
date.
Biofilm formation
Biofilm formation on indwelling medical devices represents a
significant risk for invasive infections by Candida spp, since biofilms
display both increased drug tolerance and represent a persistent
source of shedded cells that disseminate via the blood stream [71–
73]. Hence, mutants in the deletion collection were scored for their
ability to form biofilms. Strains were induced to form biofilms in
96-well polystyrene plates in minimal medium at 37uC; the biofilm
biomass was quantified by determining the metabolic activity
using a fluorescein diacetate (FDA) accumulation assay [74,75].
For each strain, a relative biofilm-forming index was calculated
using FDA hydrolysis data from at least two independent cultures
of the independent deletion mutants for each gene (see Materials &
Methods; Table S8, S9, S10). Independent deletions of the same
gene including duplicates showing strong variations in relative
biofilm formation between independent assays or independent
cultures (Table S8) were omitted from further analysis, leaving 420
deletions for which biofilm production was analyzed in detail
(Figure 3; Table S9).
Out of these, 341 gene deletions resulted in a relative biofilm
forming index within two standard deviations (SD) of the average
relative biofilm-forming capacity (Figure 3; Table S10), suggesting
that the corresponding genes do not contribute to biofilm
formation in minimal medium at 37uC. Isolates for the 46 gene
deletions that resulted in an alteration in biofilm formation (i.e. a
biofilm fitness score 2 SD below or above the average relative
biofilm-forming index) but not of planktonic growth at 30uC were
retested in quadruplicate for their ability to form biofilms.
Moreover, the planktonic growth rate of these strains in minimal
medium at 37uC was monitored to assess possible effects of the
higher incubation temperature on biofilm formation. Notably,
four of the corresponding deletion strains, namely those corre-
sponding to FKH2, PKH2, SNF1 and ACE2, also displayed
temperature-sensitive phenotypes and may therefore not be solely
biofilm-specific. Yet, this analysis identified 14 gene deletions that
resulted in significant defects in biofilm formation but no
significant defect in planktonic growth, including AVO2, BCY1,
CCW12, CCH1, CNB1, DCW1, GAS1, MHP1, PKH2, SLM1, SUB1,
UTP14, YNL300W and YOR1 (Table S9). Remarkably, we
identified 11 gene knock-outs resulting in a gain in biofilm
formation without an increase in planktonic growth, including
BPH1, GAL11, GPB2, MIG1, PEX2, SSN2, SSN8, STE20, YAP6,
YDR134C and YVC1 (Table S9).
Susceptibility to azole and AmB antifungal drugs
Azoles and AmB remain the most common drugs for treating
fungal infections. The inherently reduced azole susceptibilities of
most C. glabrata clinical isolates is considered a major contributor
to the increasing clinical prevalence of this pathogen [76]. While
this is mainly the consequence of transcriptional upregulation of
the CDR1 and PDH1 (CDR2) encoding membrane efflux pumps or
gain-of-function mutations in the PDR1 regulator [28], additional
mechanisms may play a role. The polyene AmB is thought to
impair membrane function by binding to ergosterol, resulting in
cellular leakage of cytoplasm [77]. While C. glabrata can develop
AmB tolerance [78,79], the underlying molecular mechanisms
remain obscure. We have thus used the C. glabrata deletion
collection to identify genes modulating azole as well as AmB
susceptibility.
A total of 14 deletion strains displayed marked hypersensitivities
to azoles such as fluconazole and voriconazole albeit to a different
extent (Figure S5A, C; Figure 4B). Moreover, 13 mutants were
hypersusceptible to AmB (Figure S6A, Figure 4B). The corre-
sponding mutants were retested using microdilution assays to
quantify their IC50 values (Figure S5B, D; Figure S6B). The
majority of the 14 azole-sensitive strains were sensitive to both
fluconazole and voriconazole (Figure S5A, C), while 6 strains (ktr2,
cwh41, ssd1, ktr6, hap1 and slt2) appeared more sensitive to
voriconazole. Notably, the strain lacking the KTR2 gene encoding
a mannosyltransferase [80] displayed the most significant vor-
iconazole-specific hypersensitivity (Figure S5C, D). As expected,
deletion of either the PDR1 transcription factor or its target CDR1
efflux pump resulted in marked azole hypersensitivity (Figure 4B,
Figure S2, S8D). Furthermore, calcineurin pathway mutants such
as cna1 and cnb1 also displayed pronounced azole hypersensitiv-
ities, as also shown by previous reports [32,81]. Several additional
signaling mutants (slt2, wsc1, ypk1, cka2), as well as cell wall mutants
(ktr2, cwh41, ssd1, ktr6) displayed slight to intermediate azole
hypersensitivities (Figure S5A, B; Figure 4B). Among the 13 AmB-
sensitive strains, the five genes displaying the most pronounced
susceptibilities play diverse roles in phospho- and sphingolipid
signaling, including YPK1, CKA2, DEP1, SNF6 and VPS15.
Cell wall stress, osmostress and heat sensitivity
The fungicidal echinocandins stand out as the most efficient
clinically used drugs that block cell wall glucan biogenesis. Thus,
we subjected the deletion collection to profiling for susceptibilities
to the caspofungin (CF) echinocandin, as well as other cell wall
stressors such as CR and CW (Figure 4, Figure 5, Figure S7). A
total of 12 mutants were strongly hypersensitive to CR, and six to
CW (Figure 4A; Figure S7C). Unsurprisingly, deletion of genes
encoding functions implicated in cell wall integrity or polarity
(PSA1, KRE1, CWH41, OST3, KTR2, MNN10, ANP1, CBK1)
conferred hypersensitivity to CR and/or CW. Strikingly, we
identified 48 mutants with altered CF susceptibilities (Figure 4A,
Fungal Pathogen Gene Deletion Collection
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B), 38 of which were strongly hypersensitive, while another 10
were mildly CF-sensitive, including RTG3, YFH1, TNA1, ATM1,
SNF6, CRZ1 (Figure 4, Figure S7).
To identify the functionally overlapping mutants, we used
hierarchical clustering of stress-induced phenotypes, including
heat, CF, CR and CW, identifying some 106 putative chemical-
Figure 4. Classification of C. glabrata chemogenetic profiles. (A) Overlap between the chemical-genetic profile of CF (38 genes), CR (12 genes)
and CW (6 genes). 28 genes (labeled in bold letters) were novel CF tolerance genes, since they have not been previously associated with
echinocandin hypersensitivity in S. cerevisiae or C. albicans. (B) Overlap between the chemical-genetic profile of CF, azoles and AmB. 61 genes
displayed an increased sensitivity to CF (38 genes plus 10 genes with weak sensitivity), azoles (14 genes; fluconazole and voriconazole) and AmB (13
genes). The mutant strain collection was screened in a 96 well microplate format using an endpoint assay and medium was supplemented with 5 mg/
ml fluconazole, 100 ng/ml voriconazole and 1,5 mg/ml AmB. The OD600 was determined after 24 and 48 hours of incubation at 30uC. Grey-colored
genes only display a weak sensitivity phenotype or were excluded from further analysis due to strong variations in the screening. Nodes represent
compounds or genes and edges indicate chemical-genetic interactions. Gene nodes are color-coded according to GO annotation. Venn diagrams
summarize distribution of genes affecting resistance to one of the three compounds.
doi:10.1371/journal.ppat.1004211.g004
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genetic interactions (Figure 5). The clustering approach identified
three subsets of deletion mutants displaying distinct but partially
overlapping hypersensitivities to high temperature, CR, CW and
CF (Figure 5). Remarkably, the profiling analysis revealed some 28
novel CF tolerance genes, none of which had previously been
associated with echinocandin hypersensitivities in S. cerevisiae,
C. albicans or in other fungal pathogens (Figure 4, Figure 5).
Importantly, CF sensitivity phenotypes of a subset of these mutants
were confirmed in different strain backgrounds, including unre-
lated clinical isolates (Figure 6, Figure S8). Furthermore,
restoration of the wild type phenotypes upon reintroduction of
the corresponding genes confirmed that the observed caspofungin
sensitivity in deletion strains is specifically caused by the lack of the
respective gene (Figure S9). Notably, the group of genes affecting
CF sensitivity contained several genes operating in the PKC cell
integrity signaling pathway (WSC1, SLT2, BCK1, MKK1), in
calcium/calcineurin signaling (CNA1, CNB1, MID1, CCH1),
general cell wall homeostasis, including mannosylation and
glycosylation (MNN10, ANP1, MNS1, MNT3, PMT2, PSA1,
KRE2), as well as transcriptional regulators (RLM1, DEP1, POP2,
SPT3, MCM1, SIP3, SNF1). Interestingly, deletion of several genes
encoding components of the chromatin and histone modification
machinery (RPD3, HEK2, MPS3, SDS3, SIN3, ASF1) also
modulated CF susceptibility, suggesting an important regulatory
role for chromatin in controlling surface homeostasis and CF
susceptibility, as recently demonstrated for the C. albicans Hat1
acetyltransferase [82]. The removal of only four genes (WSC1,
CNB1, CNA1 and PSA1) resulted in sensitivity to all three cell wall
stressors (Figure 4A), confirming the pivotal roles PKC and
calcineurin signaling pathways play in sensing and maintaining cell
wall homeostasis in fungal pathogens [36,83,84].
Notably, the heat stress profiling on plates identified several
genes implicated in cell wall biogenesis and organization, including
CWH41, ALG5, OST3, ALG6, KTR2, BIG1, CBK1 and ALG3.
Figure 5. Clustering of susceptibility data of the C. glabrata gene deletion collection. The set of mutants was screened on plates for
hypersensitivity to four distinct stress conditions (CF, CR, CW and 42uC heat stress) using serial dilution assays on agar plates. (A) Two-dimensional
hierarchical cluster plot of chemical-genetic profiles. On the horizontal axis genes are listed and stress conditions on the vertical axis. Interactions are
shown in yellow depending on the degree of growth sensitivity (yellow=no growth, black =WT growth). Stress conditions and genes are clustered
by the similarity of their interactions. (B) The clusters of genes are enlarged to highlight the chemical-genetic interaction profile of Caspofungin (blue
bar in ‘a’ labeled ‘b’). (C) A section of the cluster (orange bar labeled ‘C’) involved in heat stress (42uC) is enlarged. (D) Genes implicated in sensitivity to
the cell wall-perturbing agents CR and CW (red and green bar labeled ‘D’).
doi:10.1371/journal.ppat.1004211.g005
Figure 6. Caspofungin sensitivity of C. glabrata clinical isolate deletion strains. Sensitivities of deletion strains constructed in clinical isolates
(KK004, KK006, KK045 and KK047) or in the ATCC2001 strain were tested for caspofungin (CF) susceptibility on plates. Strains were spotted in serial
dilutions on synthetic agar medium supplemented with the indicated CF concentrations and growth was monitored for 3 days at 30uC. Screening
was performed for (A) CCH1, (B) MID1, (C) DEP1, (D) PMT2, (E) SLA1, (F) MNS1, (G) MNT3 and (H) ANP1.
doi:10.1371/journal.ppat.1004211.g006
Fungal Pathogen Gene Deletion Collection
PLOS Pathogens | www.plospathogens.org 9 June 2014 | Volume 10 | Issue 6 | e1004211
Interestingly enough, this gene set showed some overlap with the
CF, CR or CW gene clusters (Figure 5), suggesting that heat stress
triggers partially overlapping signaling response pathways, ranging
from stress and cell integrity signaling to cell wall homeostasis and
membrane lipid perturbation.
Moreover, we also identified remarkably strong osmosensitivity
phenotypes caused by the loss of genes that have never been linked
to osmostress in other fungi before, including ATM1, ARB1, KRE1,
ANP1, MPS3 and PTR3 (Figure S3). These data suggest that even
the highly conserved fungal osmosensing pathway has acquired
additional and/or novel components in C. glabrata.
Discussion
C. glabrata is an important human fungal pathogen and, after
C. albicans, the second-most frequent cause of candidiasis, causing
15–30% of infections in humans [1–4]. Although C. glabrata
appears similar to S. cerevisiae concerning gene synteny and
conservation it is an obligate haploid, and the lack of a sexual
cycle and elevated rates of non-homologous recombination have
prevented a systematic genetic analysis. Importantly, the decreased
sensitivity of C. glabrata clinical isolates to azole antifungals is at
least in part responsible for its clinical significance [33], and recent
clinical reports suggest that azole antifungal resistance in C.
glabrata, including multidrug resistance, is emerging at a rapid
pace, thus posing an important challenge to therapeutic manage-
ment [40,85].
To aid in addressing these issues, as well as to better understand
virulence properties, we have generated a large-scale deletion
collection of C. glabrata representing almost 12% of the genome.
This deletion mutant collection that comprises 619 unique strains
each lacking a single gene has several advantages over known
transposon-based mutant collections [86], since each ORF is
completely removed. Thus, gene dosage effects or dominant
phenotypes from truncated protein variants are excluded. Like-
wise, aberrantly expressed proteins due to insertion in promoters,
which may result in partial loss or gain-of-function for the
corresponding gene product, are precluded. The deletion collec-
tion was subjected to extensive phenotypic profiling, with a
particular emphasis on susceptibility to major antifungal drugs,
growth and morphology phenotypes, stress response pathways, cell
wall biogenesis as well as biofilm formation, which has been
associated with the initiation and development of candidiasis [87].
Importantly, we show here the feasibility to generate a genome-
scale bar-coded gene deletion library in C. glabrata, revealing novel
genes contributing to fitness, biofilm formation, antifungal drug
resistance and several genes implicated in general cell wall
homeostasis. We found 196 mutants sensitive to at least one of
the tested conditions. In summary, 21% of the tested mutants
display altered fitness phenotypes and 19% show alterations in
biofilm formation, while only 2% exhibit abnormal cell and colony
morphology. Approximately 16% of the mutants show severe
stress-related phenotypes, including hypersensitivity to several
antifungal drugs, heat and osmostress conditions.
General fitness defects
C. glabrata and S. cerevisiae are phylogenetically closely related
[54]. Hence, many orthologous gene functions may have been
conserved between the two species. In our study, however, we
found several mutants with reduced or increased fitness in rich
media corresponding to genes whose inactivation in S. cerevisiae
resulted in entirely different or opposing phenotypes. These
include homologous genes from the RAS-PKA pathway (RAS2,
GPA2 and GPR1) and genes involved in N-glycosylation and outer
chain elongation (ALG5, KTR2 and MNN4). Moreover, several
genes known to be essential in S. cerevisiae were non-essential in
C. glabrata, although their inactivation often confers reduced fitness
or morphology defects. These include MEC1, encoding a master
DNA damage checkpoint kinase [88], and CBK1, although the
latter is only essential in the yeast background S288c [89]. CBK1
encodes a RAM network kinase that is central to the establishment
of cell polarity and involved in septum formation and cell
separation and morphogenesis [90–93]. Notably, inactivation of
the orthologous genes in C. albicans is not lethal [93–95]. Hence,
Mec1- and Cbk1-dependent regulatory networks may operate
differently between S. cerevisiae and C. glabrata and, possibly, other
hemiascomycetous yeasts. Many biological processes and regula-
tory networks in fungi have evolved under distinct evolutionary
pressures [96,97]. Because Candida spp. have evolved as opportu-
nistic pathogens of mammals, including humans, it is fair to
propose that adaptation to the host environment and immunity
surveillance may have been driving the evolution of functionally
rewired genetic regulatory networks [98].
Biofilm genes
Deletion strains displaying altered ability to form biofilms
include, as expected, several mutants lacking cell wall-related
genes, whose absence disturb normal cell wall homeostasis; not
surprisingly, these mutants also strongly altered CF susceptibility.
Lack of the putative kinase gene PKH2/CAGL0I07513g, whose
orthologue in S. cerevisiae encodes a component of the alternative
cell wall integrity pathway affected biofilm formation. In C.
glabrata, PKH2 has two additional paralogues, CAGL0G04609g and
CAGL0K06479g. While pkh2 mutants are defective in both biofilm
formation and show temperature-defective growth on solid media,
lack of the other two putative paralogues leaves biofilm formation
and temperature sensitivity unaffected (data not shown). These
data suggest that apparent PKH kinase homologues in C. glabrata
have acquired some specialization concerning their roles in sensing
cell wall integrity or regulating cell surface homeostasis.
Antifungal drug sensitivity
We generated a chemical-genetic profile of C. glabrata relevant to
the understanding of drug susceptibilities in vitro. In addition to
known genes implicated in azole resistance (PDR1, CDR1, PDH1),
the profiling for azoles revealed only a small number of novel
genes (YPK1, KTR2) mediating azole tolerance, with KTR2 even
showing a significant azole-specificity for voriconazole. Our data,
as well as data from a wealth of clinical isolates, imply that C.
glabrata utilizes a limited set of mechanisms to mount azole
resistance, with ABC transporter-mediated efflux by Cdr1 and
Pdh1 being the most important one, both in vitro and in vivo
[32,67,99–102]. However, it has been noticed that genomic
deletions conferring azole resistance when otherwise mutated or
overexpressed do not necessarily change sensitivities in the wild
type strain [103], perhaps due to genetic (functional) redundancy
or compensatory mechanisms. Thus, we cannot exclude the
existence of other mechanisms and genes promoting azole
resistance in C. glabrata.
The results from our screen, as anticipated, showed overlap with
phenotypic screens in S. cerevisiae [104] and C. albicans [105]
regarding sensitivity to CF, which belongs to the family of the
fungicidal echinocandin drugs that inhibit the fungal 1,3-b-D-
glucan synthase. Out of 38 mutants showing strong alterations in
echinocandin sensitivities, 16 correspond to genes whose ortholo-
gues in S. cerevisiae and in Candida spp (at least for FKS1) have been
linked to CF tolerance [36,104–106]. Hyperresistance to echino-
candins can result from mutations in the glucan synthase genes
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FKS1 or FKS2 [35], as well as through the PKC pathway that
mediates CF tolerance in S. cerevisiae [66] and C. albicans [107].
Accordingly, C. glabrata wsc1, slt2, mkk1, bck1, rlm1 and fks1
mutants, all lacking key genes of this central pathway, are also
hypersensitive to CF in our assays. This overlap points to
commonalities in the response to CF between the three species,
and also serves to validate the phenotypic profiling for echino-
candin susceptibility. Remarkably, 28 genes whose deletion
resulted in marked hypersensitivity to CF in C. glabrata have not
previously been associated with CF susceptibility in S. cerevisiae or
other fungi including C. albicans [105]. Some of these apparent
differences between species likely relates to difficulties in deter-
mining CF hypersensitivity phenotypes, given that some strains
(cdc12, ace2, fkh2, cbk1) display aberrant cell morphologies or strong
growth fitness defects (kre6), all of which interfere with IC-50
quantifications. Regardless, our data clearly identify novel genes
implicated in CF tolerance, and imply that these genes may be
players in as yet undiscovered CF resistance mechanisms.
Interestingly, cells lacking chitin synthesis genes such as CHS1
were also hypersensitive to the glucan synthase inhibitor,
completely consistent with reports from S. cerevisiae [105].
Interestingly, recent data from C. albicans demonstrate a role for
chitin in regulating cell wall susceptibility to CF [108,109].
Likewise, the absence of calcineurin subunit genes CNA1 or CNB1
leads to CF hypersensitivity, indicating that calcineurin signaling is
necessary for buffering or compensating cell wall stress, perhaps by
affecting FKS1 transcript levels through the transcription factor
Crz1 [35]. In the mould Aspergillus fumigatus, a mutation or
inhibition of calcineurin enhances the antifungal potency of CF
[110]. Thus, calcineurin inhibitors may exert synergistic effects on
cell wall mutants in other fungal species. The impact of CF on
calcium signaling in C. glabrata is further confirmed by the
hypersensitivity of mutants lacking CCH1 and MID1, both of
which encode stress-induced calcium channel proteins.
In S. cerevisiae, the Ypk1-mediated signaling pathway, which is
activated by lipid-sensing [111], constitutes an alternative cell
integrity signaling pathway connected to the classical PKC
pathway [112,113]. Remarkably, C. glabrata cells lacking YPK1
and PKH2 are CF-hypersensitive, suggesting that the Ypk1-
mediated signaling plays a major role in regulating CF tolerance
or cell wall homeostasis in C. glabrata (Figure 4, Figure S7). Taken
together, these results indicate that C. glabrata employs several
signaling pathways to respond to CF-induced cell wall damage and
the required subsequent cell wall remodeling. It is therefore not
unexpected that mutants displaying CF hypersensitivities include
genes that affect trafficking of proteins or surface carbohydrate
homeostasis, including chitin deposition and biogenesis.
Genes implicated in the susceptibility to both CF and azoles
include those encoding the calcineurin subunits Cna1 and Cnb1
and the PKC pathway components Wsc1 and Slt2. These results
confirm that both pathways are necessary for a response to both
drug classes and are consistent with data in many fungi showing
the synergistic action of calcineurin inhibitors and azoles or CF
[36,81,84,114,115]. Comparison of azole-sensitive, AmB-sensitive
and CF-sensitive mutants show that only a small number of gene
deletion strains are susceptible to all three or to at least two
compounds, which is consistent with their distinct mechanism of
action. The few deletions conferring sensitivity to all three drugs
occur in genes implicated in stress signaling, and include kinases
such as Ypk1 and the mRNA-binding protein Ssd1, which is
thought to control expression of surface genes in concert with
Cbk1 [116–120]. Our results are consistent concerning the
phenotypes for the corresponding mutants in S. cerevisiae. However,
the exact molecular function of Ypk1, a mammalian SGK kinase
homologue [121], which regulates sphingolipid biosynthesis and
cell integrity pathways in S. cerevisiae, remains unclear in C. glabrata.
It is tempting to speculate though that Ypk1 is part of a kinase
network implicated in sensing and regulating membrane pertur-
bations, drug sensitivity and lipid-mediated stress signaling
[97,122].
AmB is thought to interfere with normal membrane bilayer
function by forming complexes with ergosterol [123]. Indeed, cells
deficient in membrane biogenesis or organelle dynamics may show
a synthetic fitness loss upon perturbation of the lipid composition,
potentially explaining the AmB hypersensitivity of snf7, vps15 and
sla1 mutants. A similar reason may explain the sensitivity of cells
lacking DEP1, which, in S. cerevisiae, regulates transcription of
structural phospholipid biosynthesis genes [124]. Notably, the
profiling analysis reveals a strong genetic interaction between AmB
action and genes implicated in cell wall function. AmB-sensitive
strains include mutants lacking KRE1 and SAC7, which encode
proteins implicated in glucan homeostasis, as well as KTR6, KTR2,
CWH41, whose products affect surface protein glycosylation.
Remarkably, the latter three mutants show pronounced azole
hypersensitivity, demonstrating a direct link between membrane
lipid perturbation, cell wall function and antifungal sensitivity.
The hierarchical clustering of stress-induced phenotypes caused
by heat, CF, CR and CW, identifies some 106 putative chemical-
genetic interactions (Figure 5). We expected to discover distinct
patterns for each compound, since CR and CW mainly affect cell
wall structure and composition, whereas CF targets Fks1. All
compounds strongly activate cell integrity signaling, which
together drives cell wall remodeling and regulates surface
homeostasis. Accordingly, the CF profile was enriched for genes
involved in cell wall organization, signaling and transcriptional
regulators, reflecting the activity of CF as an inhibitor of fungal cell
wall biosynthesis (Figure 4). We were surprised that only a few
genes in the CF cluster overlap with genes associated with CR and
CW sensitivity (Figure 4A), most of which are involved in stress
and cell wall signaling (CNA1, CNB1, WSC1) or cell wall biogenesis
(KRE1, PSA1, ANP1, MNN10), indicating that distinct signaling
pathways must cooperate to ensure maintenance of a functional
cell wall under various adverse conditions.
As expected, our screens for drug susceptibility and cell wall
integrity identified C. glabrata orthologues of genes implicated in
related processes in other fungi. In addition, we identified novel
genes whose functions may be specific to C. glabrata, since none of
them has been associated with drug sensitivity or cell wall
homeostasis. Because the phenotypes are in general hypersensi-
tivities, these data suggest that at least some genes may represent
feasible targets for drug discovery. The discovery of a large
number of deletion mutants affecting CF tolerance expands our
knowledge about plausible mechanisms regulating CF sensitivity.
For example, the fact that several CF-sensitive mutants are
implicated in exocytic delivery of cell wall components such as
chitin, glucan or mannan, implies a constant cross-talk of distinct
signaling pathways to control proper cell wall remodeling upon
CF-induced surface damage. As the number of chemical-genetic
and genomic data in baker’s yeast [45,46] is steadily increasing,
our data add novel information concerning the function of related
genes in an important human fungal pathogen. Hence, these data
represent an important contribution towards a better understand-
ing of drug resistance mechanisms, as well as species-specific
differences.
These large-scale phenotypic profiling data also demonstrate the
power of the C. glabrata knock-out collection, which is, in addition
to the C. albicans and C. neoformans collections [50,53], to the best of
our knowledge, among the three largest academic deletion
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collections for a human fungal pathogen. We anticipate that this
library will facilitate studies on virulence factors and other aspects
of C. glabrata biology. The use of sequence barcodes, which were
adopted from the S. cerevisiae gene deletion collection [43], allows
for the functional analysis of pools of mutants either in vitro or in
vivo [50,53]. The use of multiple auxotrophic markers, which do
not affect in vivo dissemination of strains in standard mouse models
of fungal virulence [60] will allow for construction of double or
triple mutants, and facilitate genetic interaction studies as well as
epistasis analysis of pathway architectures. Notably, screens of the
collection in different animal models and the understanding of
virulence phenotypes (or lack thereof) can be challenging and
laborious requiring a very large number of animals, due to the
potential impact of fitness defects on growth in vivo or possible
genetic redundancy. We suggest that interpretation of virulence
phenotypes will be aided by the in vitro phenotypic analysis
presented here, permitting correlation of in vitro phenotypes and in
vivo fitness effects for C. glabrata.
Similar to existing C. albicans [50] or C. neoformans [53]
collections, the C. glabrata mutant library constitutes a valuable
tool for the fungal research community to study the function of
virulence and drug resistance genes in C. glabrata. In view of rapid
changes in the epidemiology of fungal infections, with C. glabrata
infections showing ever-increasing clinical importance reaching up
to 30% prevalence in some countries [33,125], this work is the first
large-scale contribution to the systematic analysis of mechanisms
implicated in antifungal drug resistance and C. glabrata pathoge-
nicity. Notably, much of the previous work aimed at unraveling
the molecular basis of drug resistance mechanisms in C. glabrata
have been based on what is known from baker’s yeast [104,126] or
other Candida pathogens [105]. Although gene synteny has been
largely conserved between pathogenic an non-pathogenic yeasts
such as C. glabrata and S. cerevisiae, extensive rewiring of signaling
pathways generated distinct and species-specific functions for
seemingly orthologous genes. Indeed, our work clearly demon-
strates that comparing and predicting drug resistance or virulence
phenotypes for C. glabrata based on data from even related yeasts
requires extensive experimental verification and the use of loss-of-
function approaches. This fungal pathogen deletion collection will
pave the way for these future efforts.
Materials and Methods
Ethics statement
The use of clinical C. glabrata isolates was approved through
respective ethics committees according to national regulations.
Media and growth conditions
YPD (1% yeast extract, 2% peptone, 2% dextrose) media were
prepared as described elsewhere [127]. Synthetic complete (SC)
medium contained 0,67% YNB, 2% glucose supplemented with
16CSM (ForMedium; complete synthetic mixture) containing
histidine, tryptophane and leucine, which are required for growth
of the deletion strains. Plates contained 2% agar.
Bioinformatic analysis and gene selection
Genes of different functional categories were manually selected
based on potential function in virulence and drug resistance. The
categories involved genes of signaling pathways, kinases, ABC
transporters and permeases, GPI-anchored proteins, cell wall
associated genes, genes involved in glycosylation, phospholipid
biosynthesis, histone modification, iron metabolism, and several
genes with no obvious homologue in S. cerevisiae. The genes were
selected by their homology to S. cerevisiae based on these functional
categories (SGD annotations; http://www.yeastgenome.org).
C. glabrata orthologues of the selected genes were first identified
using a BLAST approach. The three best-aligned hits for each
gene were saved and the C. glabrata homologue with the highest P-
value was arbitrarily defined as the C. glabrata orthologue of a given
gene in baker’s yeast and named accordingly. In addition, a
complete catalogue of orthology and paralogy relationships
between C. glabrata genes and their homologues in 16 other
fully-sequenced fungi was derived using a phylogenetic approach
[128]. For this a complete collection of Maximum Likelihood
phylogenetic trees for all C. glabrata genes, the so-called phylome,
was generated using the automated pipeline described elsewhere
[129]. Gene phylogenies, alignments and orthology and paralogy
predictions are publicly available through PhylomeDB (http://
www.phylomedb.org).
Primer design and generation
Oligonucleotide sequences for generation of the deletion
cassettes and strain verification were automatically designed, using
a custom-written Perl script called PrimerList (W. Glaser, unpub-
lished data). PrimerList utilizes Bioperl to read and process
nucleotide sequences and uses the EMBOSS [130] programs
eprimer 3 and stssearch to find suitable primersets. For PCR-based
generation of knock-out constructs, upstream and downstream
fragments for genomic recombination were chosen to have a size
between 450 and 550 nucleotides. 5959 (forward) and 3939 (reverse)
primers were chosen to have a length of 20 to 30 bp, a GC content
between 30 and 60% and a melting temperature of 50uC64uC
with a GC clamp. 5939, 3959 primers were chosen to have a length
of 20 to 30 bp plus the 20 bp constant overlap sequence (Figure 1,
Table S3, ‘barcode sequence sheet’), a GC content between 30
and 60% and a melting temperature of 50uC64uC. 5939 (reverse),
3959 (forward) primers were chosen to bind exactly adjacent to the
coding sequence, including the start codon ATG or the stop
codon, respectively. 5c and 3c control primers have a length of 20
to 25 bp, a GC content between 40 and 60% and a melting
temperature between 50uC to 60uC. The product size of the
control PCR is between 750 and 900 bp. Internal control primers
(5i and 3i) were designed to bind inside the coding sequence and to
give a product of 400 to 500 bp in size. The primers have a length
of 20 to 25 bp, a GC content between 40 and 60% and a melting
temperature between 55uC to 60uC. Oligonucleotides were
commercially purchased in 96-well plate format (Eurogentec,
Belgium). Six plates were needed for each set. Each of the six
plates (5959, 5939, 3959, 3939, 5c, 3c) contained the primers for a
specific gene at the exact same well position.
Generation of gene deletion cassettes by fusion PCR
The dominant marker NAT1 was amplified from plasmid
pJK863 [57] using the primers fp_NAT1-U2 and rp_NAT1-D2 to
add the constant 20 bp sequences U2 and D2. The PCR product
was ligated into a pGEM-T vector (Promega), generating plasmid
pTS50. For the fusion PCR step, deletion cassettes were generated
using a modified fusion PCR protocol [51]. Briefly, 500 bp long
flanking homology regions were amplified from ATCC2001
genomic DNA with primer pairs 5959/5939 and 3959/3939 adding
the constant overlap sequence (U1/D1) of 20 bp and purified by
ethanol precipitation. The conditions for a 50 ml reaction were as
follows: 16Taq buffer (50 mM KCl, 10 mM Tris-HCl (pH 9.0,
25uC), 0.1% TritionX-100, 1.5 mM MgCl2), 0.2 mM dNTPs,
0.5 mM each primer, 1 ml Taq-Polymerase and genomic wild type
DNA from strain ATCC2001; 93uC for 5 minutes, 35 cycles 93uC
for 30 s, 45uC for 30 s, 72uC for 90 s, finally 10 minutes at 72uC.
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The dominant marker NAT1 was amplified from plasmid
pTS50 in a separate PCR reaction using primers 5M and 3M,
adding unique barcode tags and constant complementary U1 and
D1 sequences. Marker fragments were gel-purified in 0.7%
agarose gels. The conditions for a 50 ml reaction were as follows:
16 Taq buffer, 0.2 mM dNTPs, 0,5 mM each primer, 1 ml Taq-
Polymerase and plasmid TS50; 93uC for 3 minutes, 32 cycles
93uC for 30 s, 49uC for 30 s, 72uC for 2,5 minutes, finally
10 minutes at 72uC. Fusion PCR was carried out in a 50 ml
volume with the same conditions as above: 16 ExTaq buffer,
0.2 mM dNTPs, 0.5 mM each primer, 0.5 ml ExTaq-Polymerase
(TaKaRa) and 3 ml marker fragment, 1.25 ml each flanking
homology fragment; 93uC for 3 minutes, 35 cycles 93uC for
30 s, 45uC for 30 s, 72uC for 3 minutes, finally 10 minutes at
72uC. The final deletion construct was purified by ethanol
precipitation.
Complementation of C. glabrata deletion mutants
Cloning of C. glabrata ORFs in the pDONR207 vector was done
as described in [131]. Briefly, for each of the selected ORFs, a
forward primer including the attB1 site and the first 10 codons of
the ORF and a reverse primer including the attB2 site and the last
ten codons of the ORF were designed and synthesized at Pasteur-
Genopole-Ile-de-France oligonucleotide synthesis platform (Table
S13). ORFs were amplified from genomic DNA of C. glabrata strain
ATCC2001 [54] using Phusion High-Fidelity DNA Polymerase
(New England Biolabs) and 30 cycles of amplification with
elongation times varying from 1 to 3 min. according to the
ORF size. The resulting PCR products were checked by agarose
gel electrophoresis, ethanol precipitated and, following resuspen-
sion in Tris-EDTA, mixed with the donor plasmid pDONR207
(Invitrogen), and subjected to a recombination reaction with
Invitrogen Gateway BP Clonase. The recombination mixes were
transformed into E. coli strain DH5a and one transformant per
ORF was used for plasmid preparation. The cloned ORFs were
sequenced from the 59- and 39-ends using Sanger sequencing.
To construct a replicative, Gateway-compatible C. glabrata
expression vector, the C. glabrata TDH3 promoter amplified from
genomic DNA of C. glabrata strain ATCC2001 using oligos
CgTDH3p-fwd (59-GCGCCCGGTACCCAGGTGATCATAT-
CACTCACA-39) and CgTDH3p-rev (59-GGGCCGACTAG-
TGTTATGTTTGTTGTGATTTGTA-39), and a Gateway cas-
sette amplified from plasmid CIp10-PTET-GTW [132] were
cloned into the replicative vector pCgACT-14 [133], yielding
the Destination vector pCgACT-PTDH3-GTW. Transfer of C.
glabrata ORFs and the GFP ORF from pDONR207 into
pCgACT-PTDH3-GTW was as described in [131]. An aliquot of
each Entry plasmid was mixed with 50 ng of the Destination
plasmid and subjected to a recombination reaction with Invitrogen
Gateway LR Clonase. The recombination mixes were transformed
into E. coli strain DH5a and one transformant was used for
plasmid preparation. EcoRV digestion was used to verify the
cloning of the appropriate ORF. A list of the plasmids used in this
study is shown in Table S11. The expression plasmids were
transformed into the corresponding C. glabrata deletion strain
according to [134]. Transformants were selected for prototrophy.
The resulting strains are listed in Table S12.
Transformation of C. glabrata by electroporation
For transformation of the background strain HTL, we used a
modified electroporation protocol [56]. Aliquots of 50 ml of a
C. glabrata culture in YPD at an optical density of 600 nm (OD600)
of 1.3 were harvested, washed with H2O, resuspended in 16TE
buffer, 100 mM LiAc and incubated at 30uC for 30 minutes with
slow shaking (1306rpm). After addition of 250 ml 1M DTT and
further incubation at 30uC for 60 minutes (1306rpm), 40 ml of
H2O were added and the cells were harvested at 1000 g for
5 minutes at 4uC. The cells were washed with 25 ml H2O,
subsequently with 5 ml 1 M cold sorbitol, finally resuspended in
550 ml 1 M sorbitol and kept on ice until use. Sterile
electroporation cuvettes were precooled on ice and loaded with
a mix of 40–45 ml electrocompetent cells and 5–10 ml linear DNA
deletion construct (app. 2–3 mg DNA). Cells were left on ice for
10 minutes and electroporation was carried out with a BioRad
GenePulser (200V, 1.5 kV, 25 mF). For recovery, 950 ml YPD was
added and cells incubated for 4 h shaking at 30uC, before plating
on YPD supplemented with 200 mg/ml Nourseothricin (Werner
Bioagents, Jena). The plates were incubated for 48 hours at 30uC.
For auxotrophic marker constructs the cells were recovered for 1 h
at 30uC before plating on selective SC medium. Transformants
were patched on YPD/Nourseothricin plates for colony PCR. For
96-well parallel electroporation, 300 ml of culture were grown to
OD600 of 1.3, split into 50 ml aliquots and treated as described
above. For electroporation, we used a BTX Harvard Apparatus
ECM630 electroporation device with a HT-100 plate handler.
Verification by yeast colony PCR
Strains were verified by colony PCR to confirm correct genomic
integration of the deletion cassette, as well as loss of the wild type
allele according to the following protocol (Figure 1B). Transfor-
mants were patched on selective plates and incubated at 30uC for
24 h. Cells were resuspended in 40 ml PCR mix 1 (0.2 mM dNTPs,
0.5 mM of each gene specific primer 5c/3c up-/downstream of the
homology region and marker specific primer 5M/3M) and heated
for 10 minutes at 93uC. After cooling on ice, 10 ml polymerase mix
(5 ml 106PCR buffer and 1 ml Taq-Pol.) were added per reaction
and a regular PCR was performed (93uC for 5 min, 25 cycles
93uC for 30 s, 45uC for 30 s, 72uC for 90 s, final 10 min 72uC).
To verify the loss of the coding sequence (CDS), colony PCR was
essentially performed the same way. Oligonucleotides used to
screen for CDS loss bind inside the CDS to generate a product of
500 bp. All internal primers were also checked for functionality in
a separate PCR reaction, amplifying the fragment from genomic
wild type DNA.
Phenotypic profiling
For phenotypic analysis of the deletion collection, mutant cells
were re-streaked from frozen stocks and grown for 48 h at 30uC
on fresh YPD plates. Each of the three plates containing
independent transformants of the same set of genes was arrayed
into a 384-spot format serving as source plates. Phenotypic
profiling of the deletion collection was performed using a robot on
YPD plates (RoToR HDA, Singer Ltd., Roadwater, UK) or by
manually spotting (two 1:10 dilutions from 24 h culture in SC) on
SC plates supplemented with the compounds to be tested. Unless
otherwise indicated, we added 120 ng/ml CF, 50 mg/ml CW
(Sigma-Aldrich) or 250 mg/ml CR (Sigma-Aldrich) as supplements
to media from sterile stock solutions after autoclaving. Plates were
routinely incubated at 30uC for up to 3 days and scanned
photographed with S&P Imaging system (S&P Imaging, Canada),
after 24, 48 and 72 h for documentation. Primary hits were
manually rescreened for confirmation in 1:10 serial dilutions.
Exponentially growing cells were adjusted to an OD600 of 0.1.
Equal volumes of serial dilutions (1:10, 1:100 and 1:1000) were
spotted on YPD plates containing drugs and incubated as
described above.Hypersensitive mutants identified as primary hits
by robotic screening were independently re-screened manually in
96-well format, to verify growth phenotypes on agar plates
Fungal Pathogen Gene Deletion Collection
PLOS Pathogens | www.plospathogens.org 13 June 2014 | Volume 10 | Issue 6 | e1004211
containing various concentrations of xenobiotics. All manual
re-screening assays were carried out independently at least in
biological triplicates in four different laboratories, including
the confirmation of hits by serial-dilution spot assays on agar
plates or as appropriate by microdilution assays in liquid
cultures.
Azole and drug susceptibility screenings
Azole susceptibility screenings were carried out by a modified
endpoint method [135] in liquid culture in microtiter plates, using
the following drug concentrations: 4 mg/ml Fluconazole, 0.1 mg/
ml Voriconazole, (all azoles from Discovery Fine Chemicals),
3 mg/ml AmB (Discovery Fine Chemicals). Cells were grown
overnight in deep well plates to stationary phase, diluted 100-fold
in sterile water and 100 ml suspension mixed with 100 ml of 26
YPD containing a 26 drug concentration (app. 105 cells/well).
After incubation at 30uC for 24 h and 48 h, cells were
resuspended and the OD600 was measured with a Victor plate
reader (Perkin Elmer, USA).
Microbroth dilution assay for IC50 determination
To determine the IC50 of antifungal drugs a modified protocol
of the microbroth dilution assay was used [136]. Briefly, an
overnight culture was diluted 1:100 in YPD, regrown to an
OD600 of 1 and an inoculum of 2.5610
4 cells/ml was prepared.
Antifungal stock solutions were prepared in DMSO. Two fold
serial dilutions of the drugs were then prepared in water in a
deep well plate and stored at 220uC until use. 100 ml of two fold
serial drug dilutions were distributed in triplicates into a flat
bottom microtiter plate. The last wells free of antifungal drugs
served as a growth control. After adding 100 ml of the inoculum
(200 ml total volume), plates were incubated at 30uC for 24 h and
48 h in a humid environment to avoid evaporation. OD600 was
determined with a plate reader. Endpoint readings were set as
the antifungal concentrations, causing at least 90% growth
inhibition after 24 h of growth when compared to the control.
The IC50 was determined by linear regression using Graph Pad
Prism software.
Fitness analysis
Growth curves were performed in 96-well plates in a Tecan
Infinite M200 microplate reader or a Tecan Sunrise microplate
reader. C. glabrata strains were grown in YPD at 30uC. For each
96-well plate, the doubling times of each of the 96 tested strains
were calculated based on the time necessary for a given strain to
go from OD 0.15 to OD 0.6. The relative fitness of a strain was
then calculated as the ratio of the average doubling time of all
strains within the third to eighth deciles to the doubling time of
the strain of interest [68]. Means and standard deviations are
presented for fitness values determined for one or two indepen-
dent knock-out mutants in two biological replicates. Strains with
standard deviation above 0.1 or an absolute difference between
the relative fitness of two independent knock-out mutants above
0.1 were not considered further. In order to identify among the
remaining strains those that showed significantly increased or
decreased fitness, the average and standard deviation of the
fitness for strains within the second to ninth deciles were
calculated. Strains were classified based on the number of
standard deviation between their fitness and the average fitness.
Strains with decreased fitness had a fitness at least two standard
deviations below the average fitness. Strains with increased fitness
had a fitness at least two standard deviations above the average
fitness.
Biofilm formation assays
Biofilms were produced in 96-well plates as previously described
[75]. Briefly, saturated cultures in YPD were pin-inoculated
diluted in 100 ml SD 0.4% glucose medium in 96-well polystyrene
plates and incubated at 37uC for 24 h. The 96-well plates were
then washed with PBS using a HydroFlex platform (Tecan) and
100 ml of a 16 FDA solution (506 stock: fluorescein diacetate,
2 g l21 in acetone; diluted to 16 in PBS) was added per well [74].
Plates were wrapped in aluminium foil and incubated for 1 h at
37uC before measuring fluorescence in a Tecan Infinite M200
microplate reader using an excitation filter of 48669 nm and an
emission filter of 535620 nm. The relative biofilm fitness of a
strain was then calculated as the ratio of the OD535 nm recording
for the strain of interest to the average of the OD535 nm recordings
obtained for strains within the third to eighth deciles of all
OD535 nm recordings obtained within the 96-well plate to which
the strain of interest belonged. Means and standard deviations are
presented for fitness values determined for one or two independent
knock-out mutants in two biological replicates. Strains with
standard deviation above 0.3 or an absolute difference between
the 2–4 relative biofilm fitness values above 0.5 were not
considered further. In order to identify among the remaining
strains those that showed significantly increased or decreased
ability to form biofilm, the average and standard deviation of the
relative biofilm fitness for strains within the second to ninth deciles
were calculated. Strains were classified based on the number of
standard deviation between their biofilm fitness and the average
biofilm fitness. Strains with decreased biofilm fitness had a relative
biofilm fitness at least two standard deviations below the average
relative biofilm fitness. Strains with increased biofilm fitness had a
relative biofilm fitness at least two standard deviations above the
average fitness. Strains with decreased or increased biofilm fitness
were further evaluated by performing a biofilm assay in
quadruplicate for each of two independent isolates. Data obtained
for the 58 candidate strains were compared to those obtained for
wild type isolates (96 independent values) using the Wilcoxon test.
A p value below 0.01 was considered as indicative of a significant
difference with the wild type strain. In this assay, a yak1D mutant
was found significantly impaired in biofilm formation while a sir3D
mutant showed significantly elevated biofilm production as
previously shown [75].
Supporting Information
Figure S1 Generation of the new triple auxotrophic
strain HTL. (A) Cloning strategy using the SAT1 flipper for
recyclable deletion cassettes of C. glabrata TRP1, LEU2 and HIS3
genes. 500 bp homology flanking regions were ligated into ApaI/
XhoI and SacII/SacI restriction sites in pSFS2a, the deletion
cassette excised with ApaI/SacI and the resulting fragment used to
transform C. glabrata ATCC2001. (B) Growth of ATCC2001 wild
type strain, HTL and HTL reference strain on YPD, supplement-
ed with 200 mg/ml Nourseothricin and SC plates lacking histidine,
leucine or tryptophan. (C) Growth of ATCC2001 wild type, HTL
and HTL reference strains at 30uC and 37uC on solid YPD and
minimal medium (YNB, ammonium sulfate, glucose, histidine,
leucine or tryptophan), as well as in liquid YPD at 30uC and 37uC.
(TIF)
Figure S2 Verification of C. glabrata sensitivities to
antifungals and hyperosmolarity. Deletions were tested for
(A) osmostress (NaCl), (B) fluconazole (Flc) and (C) CF suscepti-
bility. Serial dilutions of C. glabrata ATCC 2001, HTL and selected
deletion strains were spotted onto YPD plates supplemented with
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the indicated compounds. Plates were incubated for two days at
30uC.
(TIF)
Figure S3 Sensitivity of C. glabrata strains to NaCl
treatment. Confirmation of NaCl sensitivities of osmosensitivity
mutants on agar plates. Deletions strains were spotted in serial
dilutions on synthetic medium supplemented with 1M NaCl and
growth was monitored over 3 days at 30uC.
(TIF)
Figure S4 Deletions with altered fitness under plank-
tonic or biofilm growth conditions. VENN diagrams
showing the overlap between planktonic and biofilm growth. (A)
36 strains showed a decrease in fitness in biofilm conditions, while
55 strains show a fitness decrease in planktonic conditions. 13
strains showed a decrease in fitness under both conditions. (B) 36
mutants displayed a fitness gain under biofilm conditions, while 35
mutants showed increased fitness under planktonic conditions. 8
strains showed an increase in both growth conditions. SD
(standard deviation), Fb (fitness biofilm growth), F (fitness
planktonic growth).
(TIF)
Figure S5 Susceptibilities of C. glabrata mutants to
azoles. Susceptible strains identified in the primary screenings
were subjected to IC50 determination. Overnight cultures were
grown to an OD600 of 1.0 and a microdilution assay was carried
out in YPD to determine IC50 values as described in Materials &
Methods. The OD600 was determined in a microplate reader after
24 h and 48 h of incubation at 30uC. Each strain was tested in
triplicates and mean values normalized to the untreated control
were plotted against the antifungal concentration of fluconazole
(A) and voriconazole (C). The IC50 was calculated by nonlinear
regression (curve fit), using GraphPad Prism for fluconazole (B)
and voriconazole (D). Shown are data of 24 h measurements. Bars
denote standard deviations.
(TIF)
Figure S6 Susceptibilities of C. glabrata mutants to
AmB. AmB-susceptible strains identified in the primary robotic
screening were subjected to IC50 determination. Overnight
cultures were grown to an OD600 of 1.0 and a microdilution
assay carried out in YPD to determine IC50 for AmB (A) as
described in Materials & Methods. The OD600 was determined in
a microplate reader after 24 h and 48 h of incubation at 30uC.
Each strain was tested in triplicates and mean values normalized to
the untreated control were plotted against the antifungal
concentration. The IC50 were calculated for each mutant by
nonlinear regression (curve fit), using GraphPad Prism (B). Shown
are data of 24 h measurement. Bars indicate standard deviations.
(TIF)
Figure S7 Sensitivity of C. glabrata deletion strains to
cell integrity stressors. Deletion strain sensitivities were tested
against CF, CW, CR, and 42uC in liquid culture and on plates. (A)
Growth susceptibilities of C. glabrata strains to CF. Susceptible
strains identified in the primary robotic screenings were subjected
to IC50 determination. Overnight cultures were grown to OD600 of
1.0 and a microdilution assay was carried out in YPD to determine
IC50 as described in Materials & Methods. The optical density
(OD) of each well was determined at 600 nm on a microplate
reader after 24 h and 48 h of incubation at 30uC. Each strain was
tested in triplicates and mean values normalized to the untreated
control were plotted against the antifungal concentration. The
IC50 was calculated by nonlinear regression (curve fit), using
GraphPad Prism. Shown are data of 48 h measurement. Bars
denote standard deviations. (B) Confirmation of CF sensitivity on
plates. Strains were spotted in serial dilutions on synthetic medium
supplemented with 120 ng/ml caspofungin (CF) and growth was
monitored over 3 days at 30uC. (C) Congo Red (CR), heat and
Calcofluor White (CW) sensitivity on plates. Strains were spotted
in serial dilutions on synthetic medium supplemented with
250 mg/ml Congo Red (CR) or 50 mg/ml CW and growth was
monitored over 3 days at 30uC. For heat stress assay cells were
grown at 42uC over three days.
(TIF)
Figure S8 Caspofungin and azole sensitivities of C.
glabrata deletions in different genetic backgrounds.
Sensitivities of deletion strains constructed in the HTL (a) and
the his3 (b) background strains were tested for caspofungin (CF),
fluconazole (Flc) and voriconazole (Vor) susceptibility on plates.
Strains were spotted in serial dilutions on synthetic medium
supplemented with the indicated drug concentrations, and growth
monitored for 3 days at 30uC. Screening was performed for (A)
RPD3, (B) CRZ1, (C) RLM1 and (D) PDR1.
(TIF)
Figure S9 Caspofungin sensitivity of C. glabrata rever-
tant strains. Sensitivities of deletion strains carrying the
corresponding wild type gene or a control plasmid containing
GFP were tested for caspofungin (CF) susceptibilities on plates.
Strains were spotted in serial dilutions on synthetic medium
supplemented with CF and growth was monitored over 3 days at
30uC. HTL GFP: HTL control strain carrying GFP-containing
plasmid;
(TIF)
Table S1 Classification of functional gene categories.
Genes were selected by their homology to S. cerevisiae based on
SGD gene ontology annotations (http://www.yeastgenome.org).
C. glabrata orthologues were identified using a BLAST approach.
The three best-aligned hits for each gene were saved according to
decreasing P values. The orthologues have been remapped using a
tree-based approach applying the algorithm described in [50,53].
A total number of 1047 C. glabrata genes were subjected to gene
disruption.
(DOC)
Table S2 C. glabrata background recipient strains used
in this study. The triple auxotrophic strain HTL and isogenic
single and double deletion strains were generated in the sequenced
reference strain ATCC2001. Strain HTL was used as recipient
strain for the generation of the deletion mutants in the strain
library. All other strains of the deletion strain collection are
deposited in the C. glabrata deletion strain library (http://funpath.
cdl.univie.ac.at) and listed in Table S3.
(DOC)
Table S3 Summary of auxotrophic C. glabrata deletion
strains generated in the HTL and his3 backgrounds
derived from the clinical isolate strain ATCC2001. Sheet
1: deletion strains + corresponding barcodes. Independent
transformants of all generated gene deletion strains are listed with
corresponding UP and DOWN tags, position in storage plates,
number corresponding to the individual biological replicate
(IBR#) for a targeted gene (e.g. the second of three independent
replicates for CAGL0A01133g has IBR #2) and the nourseo-
thricin marker used. All data can be searched online under:
http://funpath.cdl.univie.ac.at. (Sheet 2: barcode sequences only).
Bar-codes used as unique genomic tags in C. glabrata deletion
strains. 2696 upstream and downstream barcodes were used for
every set of 96 gene deletion strains. These can be amplified from
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constant regions (U1+U2; D1+D2) identical in every deletion
strain. Strains labeled with BM or BG carry individual barcodes
and were made in the histidine auxotrophic strain derived from
ATCC2001.The reference strain in the HTL background carries a
unique barcode not used for any other strain. Barcode sequences




Table S4 Summary of the phenotypic screening results
of the C. glabrata deletion collection. The table shows all
deletion mutants obtained and their corresponding phenotypes.
For heat stress, CF, CR, CW and NaCl data the degree of growth
inhibition was scored from 5 (wild type) to 0 (no growth). For azole
and AmB the phenotypes were classified from 0 (wild type) to 3
(severe defect).
(XLSX)
Table S5 Fitness raw data of C. glabrata deletion
strains with strong variations in relative fitness. Deletions
displaying strong variations between independent mutants in the
same gene or independent cultures, identifying 57 strains that were
excluded from fitness analysis due to a standard deviation of more
than 0.1, or an absolute difference in fitness of more than 0.1
between two biological replicates.
(XLS)
Table S6 Fitness raw data of C. glabrata deletion
mutants. The table shows the raw data for fitness analysis,
including fitness and standard deviation (SD).The orange (.3 SD)
and red (.2,3 SD) color-coding indicates genes with deviations
below and above the average fitness indices. Grey font indicates
mutants where only a single isolate was obtained.
(XLS)
Table S7 Fitness distribution of C. glabrata knock-out
mutants. The Table shows the distribution of fitness phenotypes.
Strains with a standard deviation (SD) above 0.1 or an absolute
difference in fitness of more than 0.1 between two biological
replicates were excluded from detailed analysis. Classification was
based on the number of standard deviations between the fitness of
a single strain and the average fitness. A total of 504 deletion
strains were scored.
(DOC)
Table S8 Biofilm raw data - strains with strong
variations in relative biofilm fitness. Some 158 deletion
strains were excluded from biofilm analysis due to a standard
deviation (SD) of more than 0.3 or an absolute difference of more
than 0.5 between replicates.
(XLS)
Table S9 Biomass quantification using fluorescein
diacetate assay. The table shows the raw data for biofilm
analysis, including fitness and standard deviation (SD). Grey font
indicates mutants where only a single isolate was obtained. Strains
were reliable fitness determination at 30uC was not possible are
indicated (Pb plankto). The Planktonic (37uC) column summarizes
the results of liquid growth measurements at 37uC (Pb indicates
altered growth rate).
(XLS)
Table S10 Biofilm fitness distribution of C. glabrata
knock-out mutants. Summary of biofilm fitness phenotypes.
Strains with a standard deviation (SD) above 0.3, or an absolute
difference in biofilm fitness of more than 0.5 between replicates
were excluded. Classification was based on the number of
standard deviations between the fitness of a single strain and the
average fitness. A total of 420 deletion strains were subjected to
biofilm fitness analysis.
(DOC)
Table S11 Plasmids used in this study.
(DOC)
Table S12 Revertant strains used in this study.
(DOC)
Table S13 Oligonucleotides used for construction of
revertant strains in this study.
(DOCX)
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